Last reviewed · How we verify
Imatinib mesylate tablet 400 mg, 1 Tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Imatinib mesylate tablet 400 mg, 1 Tablet (Imatinib mesylate tablet 400 mg, 1 Tablet) — Dong-A ST Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Imatinib mesylate tablet 400 mg, 1 Tablet TARGET | Imatinib mesylate tablet 400 mg, 1 Tablet | Dong-A ST Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Imatinib mesylate tablet 400 mg, 1 Tablet CI watch — RSS
- Imatinib mesylate tablet 400 mg, 1 Tablet CI watch — Atom
- Imatinib mesylate tablet 400 mg, 1 Tablet CI watch — JSON
- Imatinib mesylate tablet 400 mg, 1 Tablet alone — RSS
Cite this brief
Drug Landscape (2026). Imatinib mesylate tablet 400 mg, 1 Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/imatinib-mesylate-tablet-400-mg-1-tablet. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab